Duality Biologics (Suzhou) Co. Ltd. (DualityBio)

	Start	2023-04-03 existent
	Industry	antibody-drug conjugate (ADC)
	Industry 2	DB-1311/BNT324 (B7-H3 ADC, Duality Biologics / BioNTech)
	Person	Zhu, John (DualityBio 202304 CEO + Founder formerly 6 Dimensions Capital)

	Region	Shanghai
	Country	China
	City	n. a.
		Address record changed: 2023-04-03

Basic data	Employees	n. a.


		Record changed: 2024-02-04

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Duality Biologics (Suzhou) Co. Ltd. (DualityBio)

[1] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
[2] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....
[3] BioNTech SE. (8/7/23). "Press Release: BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update". Mainz....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)